3188 results for «686»
3188 results
Challenging TAVI scenarios
14 Dec 2022 – From GulfPCR-GIM 2022
This GulfPCR-GIM 2022 session is for you if you want to learn more about recurrent valve migration during TAVR or TAVI with permanent pacemaker implantation, among others!
Challenging CTO cases - Session 2
14 Dec 2022 – From GulfPCR-GIM 2022
This GulfPCR-GIM 2022 session compiles 5 challenging CTO cases and explains how to handle them. Study for example a flush ostial RCA-CTO, PWS in a CTO feeding vessel, rotablation and intravascular lithotripsy in three-vessel disease with IVUS, or rotaburr incarceration.
The why and how of performing a successful TAVI case
14 Dec 2022 – From GulfPCR-GIM 2022
In this GulfPCR-GIM 2022 session, observe a 72-year-old male patient with NYHA class II exertional dyspnoea, CAD status after revascularisation, type II DM, CKD IIIB, recently admitted for decompensated HF and type II NSTEMI, who was referred to the clinic for aortic valve replacement.
Challenging ACS scenarios
14 Dec 2022 – From GulfPCR-GIM 2022
Topics in this GulfPCR-GIM 2022 session include the role of imaging in an unusual case of ACS in a young patient, PCI of an abnormal left coronary artery with AMI, embolisation of a thrombus in a non-culprit vessel during PCI in a late-presenting anterior STEMI, and...
PCI in stable CAD
14 Dec 2022 – From GulfPCR-GIM 2022
Study the two cases presented in this GulfPCR-GIM 2022 session to find out more about the importance of proper monitoring in detecting post-PCI complications and managing complex PCI and coronary stent loss.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...
Author
